MAXCYTE INC's ticker is and the CUSIP is 57777K106. A total of 98 filers reported holding MAXCYTE INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $22,128,879 | -1.2% | 5,645,122 | +5.6% | 0.00% | – |
| Q1 2024 | $22,404,399 | -9.8% | 5,347,112 | +1.2% | 0.00% | -100.0% |
| Q4 2023 | $24,825,907 | +57.9% | 5,282,108 | +4.8% | 0.00% | – |
| Q3 2023 | $15,721,204 | -31.1% | 5,038,847 | +1.4% | 0.00% | -100.0% |
| Q2 2023 | $22,816,569 | -5.7% | 4,970,930 | +1.7% | 0.00% | 0.0% |
| Q1 2023 | $24,197,942 | -8.6% | 4,888,473 | +0.8% | 0.00% | 0.0% |
| Q4 2022 | $26,470,718 | -12.7% | 4,848,117 | +3.9% | 0.00% | 0.0% |
| Q3 2022 | $30,324,000 | +88.8% | 4,665,320 | +37.4% | 0.00% | – |
| Q2 2022 | $16,061,000 | -30.0% | 3,395,510 | +3.4% | 0.00% | -100.0% |
| Q1 2022 | $22,958,000 | -28.7% | 3,284,596 | +4.0% | 0.00% | 0.0% |
| Q4 2021 | $32,177,000 | -4.3% | 3,157,690 | +14.6% | 0.00% | 0.0% |
| Q3 2021 | $33,630,000 | – | 2,754,317 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 3,225,000 | $20,963,000 | 8.46% |
| NORTH RUN CAPITAL, LP | 556,960 | $3,620,000 | 7.35% |
| Vitruvian Partners LLP | 5,043,356 | $32,782,000 | 5.85% |
| Casdin Capital, LLC | 10,735,786 | $69,783,000 | 4.58% |
| RIVER GLOBAL INVESTORS LLP | 1,867,113 | $11,880,000 | 2.28% |
| APIS CAPITAL ADVISORS, LLC | 200,000 | $1,300,000 | 1.95% |
| Pier Capital, LLC | 1,262,654 | $8,207,000 | 1.41% |
| Montanaro Asset Management Ltd | 929,000 | $6,009,000 | 0.92% |
| First Light Asset Management, LLC | 1,362,543 | $8,857,000 | 0.90% |
| Grandeur Peak Global Advisors, LLC | 1,206,013 | $7,839,000 | 0.48% |